Labcorp director Anderson sells shares for $127,817

Kerrii B. Anderson, a director at Labcorp Holdings Inc. (NYSE:LH), recently sold 500 shares of the company’s common stock. The transaction, which took place on March 5, 2025, was executed at an average price of $255.63 per share, totaling approximately $127,817. The sale comes as the $21.3 billion healthcare services provider trades near its 52-week high of $258.59, with InvestingPro data showing management has been actively buying back shares. Following this sale, Anderson retains direct ownership of 13,166 shares in Labcorp.

In addition to her direct holdings, Anderson also holds indirect ownership of 144 shares each through two separate trusts: the Alexa M. Anderson Separate Trust and the Cameron Taff Anderson Separate Trust.

In other recent news, Laboratory Corporation of America, commonly known as LabCorp, has seen several significant developments. Jefferies analyst Tycho Peterson raised the company’s price target to $290, maintaining a Buy rating, following LabCorp’s strong fourth-quarter revenues and earnings per share, which exceeded expectations. Similarly, Truist Securities increased their price target to $285, also maintaining a Buy rating, citing strong core business momentum and promising guidance for 2025. Citi analysts upgraded LabCorp’s stock from Neutral to Buy, raising the price target to $300, highlighting the company’s potential to benefit from strong utilization rates in the Labs industry.

LabCorp’s recent acquisition of Invitae (OTC:NVTAQ) is expected to initially impact margins, but analysts foresee a path to breakeven and possible future accretion. The company also launched Labcorp Plasma Complete, a liquid biopsy test for advanced cancer care, enhancing its oncology portfolio. This test, which is not FDA-cleared but developed by LabCorp, provides comprehensive genomic insights to aid personalized treatment plans. Meanwhile, Immutep (NASDAQ:IMMP) Limited reported its half-year financial results, although specific details were not disclosed in the summary. Investors can access the full report through the SEC’s EDGAR database for detailed financial data.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.